Liquid biopsy-based single-cell metabolic phenotyping of lung cancer patients for informative diagnostics
Ziming Li(Shanghai Jiao Tong University), Qihui Shi(Fudan University), Xiang Lu(Chinese Academy of Sciences), Yin Tang, Min Xue(California Institute of Technology), Wei Wei(Institute for Systems Biology), Jie Chen(Air Force General Hospital PLA), Yang Liu(Shanghai Cancer Institute), Zhuo Wang(Shanghai Jiao Tong University), Yu Dong(Shanghai Jiao Tong University), Zhili Guo(Jiaxing University), Shun Lü(Shanghai Jiao Tong University), Chunying Wang(Shanghai Jiao Tong University), Baojun Wu(Huazhong Agricultural University)
Cited by 49
Related Papers
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
|The Lancet Oncology|2011|4.1k
Osimertinib in Resected <i>EGFR</i> -Mutated Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2020|1.7k
Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials
|The Lancet Oncology|2015|1.6k